TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02049346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alpha or beta (Epoetin group)
Description: Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values \>12 and ≤13 g/dL and increased by 25% for Hb \<11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb \<10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study.
Study: NCT01881009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed-loop System
Description: Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
Study: NCT01818986

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation
Study: NCT01888744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hP-hMG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hP-hMG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: induction of final oocyte maturation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: induction of final oocyte maturation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Study: NCT01881009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Closed-loop System
Description: Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump
Description: Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
Study: NCT00353301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib hydrochloride
Description: Patients will receive single-agent Tarceva, 150 mg/day
Study: NCT00715884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER® ELITE™ Sirolimus-Eluting Stent System
Description: Drug eluting stent
Study: NCT00353301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
Study: NCT01132846

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial.
Study: NCT00715884

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
Description: Drug eluting stent
Study: NCT02918591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozine
Description: All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
Study: NCT01132846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
Study: NCT04471376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex group received a rocuronium infusion producing blockade by qualitative train-of-four ≥2 at the ulnar nerve. 2 mg/kg of Sugammadex will be infused when conducting TcMEP
Study: NCT04351932

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow mesenchymal stem cells
Description: intrarticular bone marrow mesenchymal stem cells injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adipose Mesenchymal stem cells
Description: intrarticular adipose mesenchymal stem cells injection
Study: NCT03375138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Specified dose on specified days
Study: NCT02313415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UC-MSCs therapy
Description: Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
Study: NCT01015820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EGD with EUS
Description: EUS was performed in order to measure blood flow in duodenum.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EGD with EUS
Description: EUS was performed in order to measure blood flow in duodenum.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4D-ELF
Description: During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.

Intervention type: DEVICE
Group type: OTHER
Intervention: 4D-ELF
Description: During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
Study: NCT02910219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer
Description: Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
Study: NCT03862222

Intervention type: OTHER
Intervention: Pupillometry
Description: Participants will complete a task studying pupillary response to light
Study: NCT01347632

Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
Study: NCT05599113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy
Description: Extracorporeal shock wave therapy (ESWT) is an expedient remedy that is used in various joint and non-invasive muscle pain treatments
Study: NCT04101669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESET Liner
Description: The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patient receives upper endoscopy but no treatment
Study: NCT02077504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEG and MRI
Description: CONDUCTOME
Study: NCT01170312

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous conditioned plasma (ACP)
Description: ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
Study: NCT04130438

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
Study: NCT01170312

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline injection
Study: NCT04130438

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
Study: NCT04048629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) viral load (VL) testing plus refresher training
Description: VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care central laboratory VL testing plus refresher training
Description: VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
Study: NCT03228706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Know Your Medicine - Take It For Health (KYM-TIFH)
Description: The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska \& Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen \& Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
Study: NCT03989856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-0 polyglican absorbable sutures
Description: The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diathermy
Description: bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
Study: NCT03175562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial micellar cleanser
Description: Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.

Intervention type: OTHER
Group type: OTHER
Intervention: Saline Solution: Sodium Chloride (NaCl; 0.9%)
Description: Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
Study: NCT00844324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
Study: NCT02109068

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling- Phone
Description: The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling- In-Person
Description: The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change.
Study: NCT03862222

Intervention type: OTHER
Intervention: Pupillometry
Description: Participants will complete a task studying pupillary response to light

Intervention type: OTHER
Intervention: Contrast Sensitivity
Description: Participants will complete a task evaluating contrast sensitivity

Intervention type: OTHER
Intervention: Contrast Sensitivity
Description: Participants will complete a task evaluating contrast sensitivity
Study: NCT02540512

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture
Description: The ASP needles will be double taped onto the ear for this procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydrocodone / acetaminophen 5mg/325mg
Description: Narcotic/NSAID medication used as the standard medical treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone / acetaminophen 5mg/325mg
Description: Narcotic/NSAID medication used as the standard medical treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pill
Description: Pills will be filled with methylcellulose and administered as a placebo for this intervention.
Study: NCT04965792

Intervention type: OTHER
Intervention: Screening
Description: Blood test
Study: NCT03741907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAUCS
Description: extraperitoneal cesarean with a paramedian left section

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MLC
Description: Gold standard
Study: NCT02097628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tidal volume
Description: In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peak airway pressure
Description: In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
Study: NCT01119196

Intervention type: OTHER
Group type: OTHER
Intervention: Icodextrin dialysate
Description: use of alternate SOC dialysate
Study: NCT00886860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
Study: NCT01746381

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive home ventilation
Description: A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive home ventilation
Description: A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
Study: NCT03754556

Intervention type: DEVICE
Intervention: Intrauterine device
Description: Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
Study: NCT01174979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caroverin
Description: treatment with eardrops 2 times for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caroverin
Description: treatment with eardrops 2 times for 48 hours
Study: NCT01413711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
Study: NCT03238703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene Citrate
Description: Given PO
Study: NCT01440114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
Study: NCT00770562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT04444271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: 1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of normal saline will be given intravenously to control arm